Aging (Albany NY)

1. DONG Y, Wu X, Xu C, Hameed Y, et al
   Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
   Aging (Albany NY). 2024;16:2591-2616.
   

   >> Share

   
   

   
   Ann Diagn Pathol

2. PALIOGIANNIS P, Lobrano R, Bella MA, Fara A, et al
   PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
   Ann Diagn Pathol. 2024;69:152267.
   

   >> Share

   
   

   
   Ann Surg Oncol

3. OMURA M, Kosaka T, Kobayashi H, Shigeta K, et al
   Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2024 Feb 20. doi: 10.1245/s10434-024-15009.
   

   >> Share

   
   

   
   Anticancer Agents Med Chem

4. FAN N, Zhang L, Wang Z, Ding H, et al
   Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage.
   Anticancer Agents Med Chem. 2024;24:348-357.
   

   >> Share

   
   

   
   Anticancer Drugs

5. WANG X, Song D, Zhu B, Jin Y, et al
   Urinary exosomal mRNA as a biomarker for the diagnosis of bladder cancer.
   Anticancer Drugs. 2024 Feb 23. doi: 10.1097/CAD.0000000000001571.
   

   >> Share

   
   

   
   Arch Esp Urol

6. LIN R, Fu X, Huang J
   Relationship between Changes of Serum Vascular Endothelial Growth Factor and Folate Receptor-alpha Levels and Clinical Efficacy of Toripalimab in Patients with Bladder Cancer.
   Arch Esp Urol. 2024;77:31-37.
   

   >> Share

   
   
7. LI Q, Su X, Qing L, Xu W, et al
   HER2 Affects the Biological Behaviours of Bladder Cancer Cells and is Closely Associated with the Progression and Prognosis of Bladder Cancer.
   Arch Esp Urol. 2024;77:79-91.
   

   >> Share

   
   

   
   BJU Int

8. CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
   Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
   BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
   

   >> Share

   
   

   
   BJUI Compass

9. ABUHASANEIN S, Jahnson S, Kjolhede H
   Shortened time to diagnosis for patients suspected of urinary bladder cancer managed in a standardized care pathway was associated with an improvement in tumour characteristics.
   BJUI Compass. 2023;5:261-268.
   

   >> Share

   
   
10. MIYAKE M, Kitamura H, Nishimura N, Miyamoto T, et al
    Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
    BJUI Compass. 2023;5:269-280.
    

    >> Share

    
    

    
    BMC Surg

11. YAO Q, Jiang H, Niu H, Hu G, et al
    Prospective learning curve analysis of en bloc resection of bladder tumor using an ex vivo porcine model.
    BMC Surg. 2024;24:65.
    

    >> Share

    
    

    
    Cancer Invest

12. XU H, Sun D, Zhou D, Sun S, et al
    Immune Cell Infiltration Types as Biomarkers for the Recurrence Diagnosis and Prognosis of Bladder Cancer.
    Cancer Invest. 2024 Feb 23:1-13. doi: 10.1080/07357907.2024.2308161.
    

    >> Share

    
    

    
    Cancer Med

13. KANG NW, Feng YH, Lin KL, Chen YC, et al
    Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
    Cancer Med. 2024;13:e6972.
    

    >> Share

    
    

    
    Cell Commun Signal

14. BODDU VK, Zamzow P, Kramer MW, Merseburger AS, et al
    Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells.
    Cell Commun Signal. 2024;22:129.
    

    >> Share

    
    

    
    Cell Rep Med

15. GALSKY MD, Guan X, Rishipathak D, Rapaport AS, et al
    Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
    Cell Rep Med. 2024;5:101393.
    

    >> Share

    
    

    
    Chem Res Toxicol

16. RAGI N, Walmsley SJ, Jacobs FC, Rosenquist TA, et al
    Screening DNA Damage in the Rat Kidney and Liver by Untargeted DNA Adductomics.
    Chem Res Toxicol. 2024;37:340-360.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

17. YUAN H, Wang T, Peng P, Xu Z, et al
    Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment.
    Clin Genitourin Cancer. 2024 Jan 22:S1558-7673(24)00012.
    

    >> Share

    
    

    
    Curr Oncol

18. TUFANO A, Rosati D, Moriconi M, Santarelli V, et al
    Diagnostic Accuracy of Contrast-Enhanced Ultrasound (CEUS) in the Detection of Muscle-Invasive Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis.
    Curr Oncol. 2024;31:818-827.
    

    >> Share

    
    
19. LIDAGOSTER S, Ben-David R, De Leon B, Sfakianos JP, et al
    BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer.
    Curr Oncol. 2024;31:1063-1078.
    

    >> Share

    
    

    
    Curr Oncol Rep

20. ISALI I, Helstrom EK, Uzzo N, Lakshmanan A, et al
    Current Trends and Challenges of Microbiome Research in Bladder Cancer.
    Curr Oncol Rep. 2024 Feb 20. doi: 10.1007/s11912-024-01508.
    

    >> Share

    
    

    
    Curr Treat Options Oncol

21. BERG SA, McGregor BA
    One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.
    Curr Treat Options Oncol. 2024;25:206-219.
    

    >> Share

    
    

    
    Discov Oncol

22. LV H, Zhou X, Liu Y, Liu Y, et al
    Feasibility analysis of arterial CT radiomics model to predict the risk of local and metastatic recurrence after radical cystectomy for bladder cancer.
    Discov Oncol. 2024;15:40.
    

    >> Share

    
    

    
    Environ Res

23. BURALLI R, Ribeiro A, Cremonese C, Vineis P, et al
    Cancer mortality and premature deaths among hairdressers in Brazil.
    Environ Res. 2024;244:117942.
    

    >> Share

    
    

    
    Eur J Clin Pharmacol

24. ZHANG T, Li H, Lin C, An R, et al
    Effects of an intraoperative intravenous Bolus Dose of Dexmedetomidine on postoperative catheter-related bladder discomfort in male patients undergoing transurethral resection of bladder tumors: a randomized, double-blind, controlled trial.
    Eur J Clin Pharmacol. 2024;80:465-474.
    

    >> Share

    
    

    
    Eur Radiol

25. HUANG J, Chen G, Liu H, Jiang W, et al
    MRI-based automated machine learning model for preoperative identification of variant histology in muscle-invasive bladder carcinoma.
    Eur Radiol. 2024;34:1804-1815.
    

    >> Share

    
    

    
    Eur Urol

26. MOSCHINI M, Necchi A, Montorsi F
    Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Eur Urol. 2024 Feb 17:S0302-2838(24)00068-X. doi: 10.1016/j.eururo.2023.
    

    >> Share

    
    

    
    Expert Opin Pharmacother

27. ABOU CHAKRA M, Duquesne I, Peyromaure M, Mott SL, et al
    Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG).
    Expert Opin Pharmacother. 2024 Feb 23. doi: 10.1080/14656566.2024.2323609.
    

    >> Share

    
    

    
    Int Braz J Urol

28. BEATRICI E, Labban M, Filipas DK, Stone BV, et al
    Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis.
    Int Braz J Urol. 2024;50:199-208.
    

    >> Share

    
    

    
    Int J Biol Sci

29. YU H, Zhuang J, Zhou Z, Song Q, et al
    METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway.
    Int J Biol Sci. 2024;20:1471-1491.
    

    >> Share

    
    
30. DU W, Tu S, Zhang W, Zhang Y, et al
    UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT.
    Int J Biol Sci. 2024;20:1389-1409.
    

    >> Share

    
    

    
    Int J Clin Oncol

31. STORMOEN DR, Joensen UN, Daugaard G, Oturai P, et al
    Glomerular filtration rate measurement during platinum treatment for urothelial carcinoma: optimal methods for clinical practice.
    Int J Clin Oncol. 2024;29:309-317.
    

    >> Share

    
    

    
    Int J Surg

32. CHEN Y, Liao Y, Yang Y, Zheng X, et al
    Letter to the editor: Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis.
    Int J Surg. 2024;110:1289-1290.
    

    >> Share

    
    

    
    iScience

33. QI D, Lu Y, Qu H, Dong Y, et al
    Independent prognostic value of CLDN6 in bladder cancer based on M2 macrophages related signature.
    iScience. 2024;27:109138.
    

    >> Share

    
    

    
    J Cancer

34. ZHOU Q, Fang L, Tang Y, Wang Q, et al
    Exosome-mediated delivery of artificial circular RNAs for gene therapy of bladder cancer.
    J Cancer. 2024;15:1770-1778.
    

    >> Share

    
    
35. YU L, Lin N, Ye Y, Zhou S, et al
    Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance.
    J Cancer. 2024;15:1734-1749.
    

    >> Share

    
    
36. TAN Z, Chen X, Li H, Huang Y, et al
    HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study.
    J Cancer. 2024;15:1624-1641.
    

    >> Share

    
    

    
    J Cancer Res Clin Oncol

37. HARSANYI S, Kianickova K, Katrlik J, Danisovic L, et al
    Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.
    J Cancer Res Clin Oncol. 2024;150:96.
    

    >> Share

    
    

    
    J Cancer Res Ther

38. DURUR S, Uzun H, Bedir R, Nalkiran I, et al
    Prognostic importance of PD-L1 expression in bladder cancer patients.
    J Cancer Res Ther. 2023;19.
    

    >> Share

    
    
39. SUTO H, Inui Y, Nishikawa S, Okamura A, et al
    Delayed diagnosis of bladder cancer in a patient with autosomal dominant polycystic kidney disease.
    J Cancer Res Ther. 2023;19.
    

    >> Share

    
    

    
    J Exp Clin Cancer Res

40. LI T, Huang M, Sun N, Hua X, et al
    Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation.
    J Exp Clin Cancer Res. 2024;43:50.
    

    >> Share

    
    

    
    J Expo Sci Environ Epidemiol

41. XIE S, Friesen MC, Baris D, Schwenn M, et al
    Occupational exposure to organic solvents and risk of bladder cancer.
    J Expo Sci Environ Epidemiol. 2024 Feb 16. doi: 10.1038/s41370-024-00651.
    

    >> Share

    
    

    
    J Med Case Rep

42. SAAD R, Ghaddar A, Zeenny RM
    Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
    J Med Case Rep. 2024;18:107.
    

    >> Share

    
    

    
    J Pers Med

43. PROIETTI F, Flammia RS, Licari LC, Bologna E, et al
    Impacts of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients with Bladder Cancer Treated with Radical Cystectomy: A Single High-Volume Center Experience.
    J Pers Med. 2024;14:212.
    

    >> Share

    
    

    
    J Pharm Biomed Anal

44. NIZIOL J, Ossolinski K, Plaza-Altamer A, Kolodziej A, et al
    Untargeted metabolomics of bladder tissue using liquid chromatography and quadrupole time-of-flight mass spectrometry for cancer biomarker detection.
    J Pharm Biomed Anal. 2024;240:115966.
    

    >> Share

    
    

    
    Med Oncol

45. RAJA D, Singh A, Kurra S, Nayak B, et al
    Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.
    Med Oncol. 2024;41:74.
    

    >> Share

    
    

    
    Medicine (Baltimore)

46. SHAO B, Wu K, Wan S, Sun P, et al
    Prediction of future research trends in bladder urothelial carcinoma: Bibliometric analysis.
    Medicine (Baltimore). 2024;103:e37176.
    

    >> Share

    
    

    
    Mol Biotechnol

47. BOTROUS S, Elmaghraby A, El-Achy S, Mustafa Y, et al
    Inhibition of TNF-alpha Oncogene Expression by Artemisia Annua L. Extract Against Pioglitazone Side Effects in Male Albino Mice.
    Mol Biotechnol. 2024;66:432-441.
    

    >> Share

    
    

    
    Mol Imaging Radionucl Ther

48. ATES SG, Demirel BB, Basar H, Ucmak G, et al
    The Added-value of Staging (18)F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.
    Mol Imaging Radionucl Ther. 2024;33:11-18.
    

    >> Share

    
    

    
    Nat Rev Urol

49. ZHANG S, Lin T, Xiong X, Chen C, et al
    Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence.
    Nat Rev Urol. 2024 Feb 19. doi: 10.1038/s41585-024-00857.
    

    >> Share

    
    

    
    Panminerva Med

50. WANG X, Wang L
    Research progress of ICIS in the treatment of bladder cancer.
    Panminerva Med. 2024 Feb 21. doi: 10.23736/S0031-0808.24.05102.
    

    >> Share

    
    

    
    Phytomedicine

51. LIU S, Wang X, Sun X, Wei B, et al
    Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1.
    Phytomedicine. 2024;126:155426.
    

    >> Share

    
    

    
    Support Care Cancer

52. HAN X, Gao K, Shang L, Wei L, et al
    Caregiver experiences of caring for family members with urostomy: a qualitative study.
    Support Care Cancer. 2024;32:167.
    

    >> Share

    
    

    
    Surg Oncol

53. CAN O, Danis E, Kutluturk EG, Polat EC, et al
    Hybrid technique has lower stricture rates than Wallace and Bricker.
    Surg Oncol. 2024;52:102036.
    

    >> Share

    
    

    
    Toxicol Pathol

54. TOSI G, Barnes JR
    Early-Onset Asymptomatic Polypoid Cystitis in Two Adolescent Male Beagle Dogs.
    Toxicol Pathol. 2023;51:357-360.
    

    >> Share

    
    

    
    Urol Case Rep

55. FALABELLA R, La Falce S, Ponti FC, Di Fino G, et al
    A rare case of muscle invasive bladder cancer in a Vescical inguinal hernia.
    Urol Case Rep. 2024;53:102673.
    

    >> Share

    
    

    
    Urol Oncol

56. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
    Reply to Shun-Fa Hung's Letter to the editor regarding the article "Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer".
    Urol Oncol. 2024 Feb 21:S1078-1439(24)00021.
    

    >> Share

    
    

    
    Urol Pract

57. NAMUGOSA M, Matthew AN, Fogg R, Klausner AP, et al
    Characterization of Cystoscopy Performance and Reporting Practices at Academic Urology Centers.
    Urol Pract. 2024;11:249-253.
    

    >> Share

    
    
58. YIP W, Assel MJ, Wong NC, Tracey AT, et al
    Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 Years of Experience.
    Urol Pract. 2024;11:356-366.
    

    >> Share

    
    

    
    Urologia

59. RT R, Sharma A, Biswal D, Goel S, et al
    Comparison of narrow band imaging versus white light imaging in detecting non muscle invasive bladder cancer.
    Urologia. 2024 Feb 19:3915603241232115. doi: 10.1177/03915603241232115.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share